A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors.
Sara M TolaneyKhanh T DoJoseph P EderPatricia M LoRussoColin D WeekesSarat ChandarlapatyChing-Wei ChangShang-Chiung ChenDenise NazzalEva SchuthFlavia BrunsteinMontserrat Carrasco-TrigueroWalter C DarbonneJennifer M GiltnaneWilliam M FlanaganS Renee CommerfordAlexander UngewickellGeoffrey I ShapiroShanu ModiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
DLYE5953A administered at 2.4 mg/kg has acceptable safety. Preliminary evidence of antitumor activity in patients with HER2-negative MBC and NSCLC supports further investigation of LY6E as a therapeutic target.